Filtered By:
Condition: Thrombosis
Procedure: Heart Transplant

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 180 results found since Jan 2013.

Thrombus on the inflow cannula of the HeartWare HVAD: an update
The HeartWare ™ HVAD™ (Medtronic, Inc., Minneapolis, MN) is a continuous-flow left ventricular assist device (LVAD) approved by the FDA in 2012 as a bridge to transplant in patients with end-stage left ventricular heart failure. The current inflow cannula has a smooth outer surface near the inflow edge and a sintered collar of titanium microspheres near the pump. A previous case series of HVAD patients bridged to transplant revealed thrombus on the outer surface of the inflow cannula in 8/8 patients, predominantly at the smooth-sintered interface, that was associated with a clinical stroke rate of 12.5% .
Source: Cardiovascular Pathology - September 14, 2018 Category: Cardiology Authors: Carolyn H. Glass, Alexander Christakis, Gregory A. Fishbein, Jaclyn C. Watkins, Kyle C. Strickland, Richard N. Mitchell, Robert F. Padera Tags: Orignal Article Source Type: research

The value of Stanford integrated psychosocial assessment for transplantation (SIPAT) in prediction of clinical outcomes following left ventricular assist device (LVAD) implantation
ConclusionIn this single-center retrospective study, SIPAT did not predict cumulative re-admissions. Further study is required to validate SIPAT before clinical implementation.
Source: Heart and Lung: The Journal of Acute and Critical Care - September 16, 2018 Category: Respiratory Medicine Source Type: research

Decannulation of a Ventricular Assist Device
BECAUSE OF the donor organ shortage, an increasing number of patients with advanced heart failure are receiving ventricular assist devices (VADs) as a bridge to transplantation or as a destination therapy.1 Patients with advanced heart failure who receive a VAD have significantly greater survival rates compared with those who are treated with only medication.2 However, short- and long-term complications of VADs still are a major concern.3 There are perioperative risks attributed to patient comorbidities; risks of surgery and anesthesia; and postoperative risks such as bleeding, thrombosis, stroke, infection, right ventricu...
Source: Journal of Cardiothoracic and Vascular Anesthesia - October 4, 2018 Category: Anesthesiology Authors: Tuan-Yen Wu Tags: Case Report Source Type: research

Unusual Techniques for Preserving Surgical and Oncologic Safety in Hepatectomy of Advanced Adrenal Malignancy with Vena Cava and Liver Invasion
We report herein three cases of major hepatectomy with IVC invasion and discuss several surgical tips.Patients and MethodsFrom March 2011 to February 2014, we retrospectively reviewed three cases of adrenal malignancy with liver and IVC invasion. Based on the severity of the malignant tumor, each case illustrates a different method to address surgical complications and maintain oncologic safety. Case 1: A 34-year-old woman was diagnosed with adrenocortical tumor during medical examination. Tumor invaded the right lobe of the liver and very close to the IVC. Fortunately, there was little thrombosis inside the IVC; we perfor...
Source: Annals of Surgical Oncology - October 1, 2018 Category: Cancer & Oncology Source Type: research

Prognostic implications of serial outpatient blood pressure measurements in patients with a left ventricular assist device
Elevated blood pressure (BP) has been linked to adverse events during left ventricular assist device support. We aimed to investigate the association between outpatient BP and stroke or suspected pump thrombosis among HeartMate II (HMII) recipients.
Source: The Journal of Heart and Lung Transplantation - November 15, 2018 Category: Transplant Surgery Authors: Alberto Pinsino, Francesco Castagna, Amelia M Zuver, Eugene A Royzman, Mojdeh Nasiri, Eric J St öhr, Barbara Cagliostro, Barry McDonnell, John R Cockcroft, A Reshad Garan, Veli K Topkara, P Christian Schulze, Koji Takeda, Hiroo Takayama, Yoshifumi Naka, Tags: Original Clinical Science Source Type: research

Prognostic implications of serial outpatient blood pressure measurements in patients with an axial continuous-flow left ventricular assist device
In this study we investigated the association between outpatient BP and stroke or suspected pump thrombosis among HeartMate II (HMII) recipients.
Source: The Journal of Heart and Lung Transplantation - November 15, 2018 Category: Transplant Surgery Authors: Alberto Pinsino, Francesco Castagna, Amelia M. Zuver, Eugene A. Royzman, Mojdeh Nasiri, Eric J. St öhr, Barbara Cagliostro, Barry McDonnell, John R. Cockcroft, A. Reshad Garan, Veli K. Topkara, P. Christian Schulze, Koji Takeda, Hiroo Takayama, Yoshifumi Tags: ORIGINAL CLINICAL SCIENCE Source Type: research

Mechanical circulatory support in the heart failure population
Purpose of review Use of durable left ventricular assist devices (LVADs) has increased considerably in recent years because of the insufficient supply of donor hearts for cardiac transplantation and improvement in outcomes from refinements in technology. This review examines clinical utility of these devices and summarizes the most recent evidence supporting the use of LVAD therapy. Recent findings There continues to be significant advancements made in LVAD technology, which has resulted in improvements in the rates of adverse events and overall patient quality of life. Specifically, less invasive and improved surgica...
Source: Current Opinion in Cardiology - February 6, 2019 Category: Cardiology Tags: HEART FAILURE: Edited by Haissam Haddad Source Type: research

Cardiovascular disease after childhood acute lymphoblastic leukaemia: a cohort study.
CONCLUSIONS: Despite attempts to reduce cardiotoxicity in childhood cancer treatment, CVD risks in ALL survivors treated more recently do not seem to have declined. PMID: 30852834 [PubMed - in process]
Source: Swiss Medical Weekly - February 24, 2019 Category: General Medicine Authors: Hau EM, Caccia JN, Kasteler R, Spycher B, Suter T, Ammann RA, von der Weid NX, Kuehni CE Tags: Swiss Med Wkly Source Type: research

Mechanical Circulatory Support Patients Awaiting Heart Transplant with Positive AT1R Antibodies Have Acceptable Outcome Post-Heart Transplant
AT1R antibodies (Abs) are known to occur in patients (pts) with heart failure. It has been reported that when AT1R Abs are detected at high levels in mechanical circulatory support (MCS) pts, MCS mortality is increased. AT1R has been associated with the development of an inflammatory state inciting thrombosis. It may be that AT1R Abs are associated with pump thrombosis or even possibly thrombotic stroke. Furthermore, it is not clear whether these pts with MCS and AT1R Abs are at increased risk for post-heart transplant complications such as primary graft dysfunction (PGD) due to the recipients ’ highly inflamed state whi...
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: D.H. Chang, J. Patel, M. Kittleson, D. Geft, S. Dimbil, R. Levine, C. Kawata, L. Czer, J. Moriguchi, D. Ramzy, J.A. Kobashigawa Tags: 502 Source Type: research

Digoxin is Associated with Decreased Survival Free from Hemocompatibility-Related Adverse Events in LVAD Patients - A Propensity Score Matched Analysis
Hemocompatibility-related adverse events (HRAEs) (stroke, suspected pump thrombosis (sPT), gastrointestinal bleeding (GIB)) reduce survival and quality of life in LVAD pts. The association between pharmacotherapy and both HRAEs and survival is poorly characterized. We aimed to assess this association in HeartMate II (HMII) pts.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: A. Pinsino, A. Gaudig, K.L. Hoffman, D. D'Angelo, E.A. Royzman, G.M. Mondellini, F. Castagna, A.M. Zuver, A.R. Garan, H. Takayama, K. Takeda, Y. Naka, R.T. Demmer, M. Yuzefpolskaya, P.C. Colombo Tags: 397 Source Type: research

A Trial of Complete Withdrawal of Anticoagulation Therapy in the Heartmate 3 Pump
The HeartMate 3 Left Ventricular Assist System has demonstrated absence of confirmed de-novo pump thrombosis and reduction in stroke. However, bleeding related adverse events persist under standard anticoagulation targeting a INR range of 2.0-3.0. In an initial experience we demonstrated safety of transition to low intensity anticoagulation (INR target 1.5-1.9, n=15, follow up of at least 6 months). Whether complete cessation of anticoagulation maintains “thromboresistance” in the HeartMate 3 pump remains unknown.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: I. Netuka, P. Ivak, Z. Tucanova, S. Gregor, O. Szarszoi, J. Rimsans, J. Connors, D. Crandall, P. Sood, M. Mehra Tags: 254 Source Type: research

Presence of Left Atrial or Left Ventricular Thrombus at the Time of CF-LVAD Implantation is Associated with Increased Post-Operative Risk of Stroke or Death
Patients with advanced HF are at increased risk for intra-cardiac thrombus formation. The impact of pre-existing left atrial (LA) or left ventricular (LV) thrombi on post-operative outcomes in LVAD patients is unknown.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: J.A. Fried, H. Lumish, A.M. Zuver, A.R. Garan, V.K. Topkara, B. Cagliostro, G. Parkis, M. Cevasco, M.T. Pineda, G.M. Mondellini, K. Ross, L. Witer, H. Takayama, K. Takeda, Y. Naka, M. Yuzefpolskaya, R.T. Demmer, P.C. Colombo Tags: 147 Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Cessation of Anticoagulation for Bleeding and Thrombosis Events with a Fully Magnetically Levitated Centrifugal Left Ventricular Assist Device
Anticoagulation therapy for patients supported by a left ventricular assist device (LVAD) has not been adequately evaluated in relevance to newer pumps, such as the fully magnetically levitated HeartMate 3 pump. Current anticoagulation guidelines target a goal INR of 2.0 –3.0 with vitamin K antagonists to mitigate the risk of pump thrombosis and ischemic stroke, but are based on historical trials with older devices. Long-term outcomes associated with newer devices, such as the centrifugal-flow HeartMate 3 (HM3), have demonstrated a marked decrease in the incidence of pump thrombosis compared to mechanical bearing axial-f...
Source: The Journal of Heart and Lung Transplantation - April 28, 2019 Category: Transplant Surgery Authors: Igor Gosev, Brian Ayers, Katherine Wood, Bryan Barrus, Sunil Prasad Tags: Case Anecdotes, Comments and Opinions Source Type: research

Shear-Mediated Platelet Activation Enhances Thrombotic Complications in Patients With LVADs and Is Reversed After Heart Transplantation
This study provides further insight into our understanding of the pathogenesis of LVAD thrombosis, addressing SMPA as a relevant key factor associated with thrombotic complications. With the PAS assay, we have identified a reliable biomarker to promote tailored pharmacological therapy for the prevention of thromboembolic events in patients with LVADs.
Source: ASAIO Journal - April 30, 2019 Category: Medical Devices Tags: Case Reports Source Type: research